- |||||||||| Trial completion date, Trial primary completion date: Follow up After Cryoablation of Small Renal Masses. (clinicaltrials.gov) - Feb 5, 2018
P=N/A, N=12, Recruiting, Terminated --> Completed Trial primary completion date: Dec 2017 --> Dec 2018 | Trial completion date: Dec 2017 --> Dec 2018
- |||||||||| Enrollment change, Trial withdrawal, Trial primary completion date: Study of High-Dose Oral Vitamin D for the Prevention of Liver Cancer (clinicaltrials.gov) - Feb 1, 2018
P1, N=0, Withdrawn, Trial primary completion date: Dec 2017 --> Dec 2018 | Trial completion date: Dec 2017 --> Dec 2018 N=24 --> 0 | Suspended --> Withdrawn | Trial primary completion date: Sep 2014 --> Feb 2016
- |||||||||| gemcitabine / Generic mfg., tadalafil / Generic mfg.
Trial completion, Metastases: Chemoimmunotherapy and Radiation in Pancreatic Cancer (clinicaltrials.gov) - Feb 1, 2018 P1, N=10, Completed, N=24 --> 0 | Suspended --> Withdrawn | Trial primary completion date: Sep 2014 --> Feb 2016 Active, not recruiting --> Completed
- |||||||||| Trial completion, Enrollment change, Trial primary completion date: Prostate Conformal Cryotherapy (clinicaltrials.gov) - Jan 31, 2018
P=N/A, N=48, Completed, Active, not recruiting --> Completed Active, not recruiting --> Completed | N=100 --> 48 | Trial primary completion date: Apr 2019 --> Jan 2018
- |||||||||| Leukine (sargramostim) / Partner Therap, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Phase classification, Combination therapy, Metastases: PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer (clinicaltrials.gov) - Jan 31, 2018 P2, N=51, Active, not recruiting, Active, not recruiting --> Terminated | Trial primary completion date: Dec 2014 --> Jan 2010; PI left UNMC Phase classification: P1 --> P2
- |||||||||| GI-6301 / BMS
Trial completion, Trial primary completion date: Cancer Vaccine Targeting Brachyury Protein in Tumors (clinicaltrials.gov) - Jan 29, 2018 P1, N=34, Completed, Recruiting --> Completed | N=24 --> 17 | Trial primary completion date: Dec 2018 --> Jun 2017 Active, not recruiting --> Completed | Trial primary completion date: Jan 2017 --> Mar 2016
- |||||||||| Phase classification, Enrollment change, Trial termination, Trial primary completion date: Endoscopic Biliary Radiofrequency Ablation of Malignant Distal Common Bile Duct Strictures (clinicaltrials.gov) - Jan 26, 2018
P=N/A, N=42, Terminated, Active, not recruiting --> Completed | Trial primary completion date: Jan 2017 --> Mar 2016 Phase classification: P2/3 --> P=N/A | N=116 --> 42 | Recruiting --> Terminated | Trial primary completion date: Nov 2016 --> Dec 2017; Poor recruitment
- |||||||||| Leukine (sargramostim) / Partner Therap, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Trial primary completion date, Combination therapy, Metastases: PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer (clinicaltrials.gov) - Jan 25, 2018 P1, N=51, Active, not recruiting, Phase classification: P2/3 --> P=N/A | N=116 --> 42 | Recruiting --> Terminated | Trial primary completion date: Nov 2016 --> Dec 2017; Poor recruitment Trial primary completion date: Jan 2019 --> Apr 2018
- |||||||||| Trial completion, Enrollment change, Trial primary completion date: Perfusion Scanning's for Kidney Tumors (clinicaltrials.gov) - Jan 24, 2018
P=N/A, N=56, Completed, Trial primary completion date: Dec 2020 --> Jul 2016 Recruiting --> Completed | N=100 --> 56 | Trial primary completion date: Dec 2018 --> Jan 2018
- |||||||||| carotuximab IV (ENV105) / Kairos Pharma
Trial completion, Combination therapy, IO biomarker: Sorafenib and TRC105 in Hepatocellular Cancer (clinicaltrials.gov) - Jan 23, 2018 P1/2, N=27, Completed, Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| TheraSphere (yttrium 90 microspheres) / Boston Scientific
Trial completion, Trial primary completion date: MispheC: Efficacy Study of Intra-hepatic Administration of Therasphere (clinicaltrials.gov) - Jan 19, 2018 P2, N=41, Completed, N=20 --> 14 | Active, not recruiting --> Terminated; The sponsor's clinical program for the agent used in this study was discontinued. Active, not recruiting --> Completed | Trial primary completion date: Sep 2017 --> Dec 2016
- |||||||||| vatalanib (PTK787) / Novartis, Bayer
Trial completion, Trial primary completion date, Combination therapy, Metastases: Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jan 17, 2018 P1, N=96, Completed, Trial primary completion date: Dec 2017 --> Dec 2018 Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Sep 2009
- |||||||||| carboplatin / Generic mfg., everolimus / Generic mfg., paclitaxel / Generic mfg.
Trial primary completion date, Metastases: Gastric Cancer RAD001 Study (clinicaltrials.gov) - Jan 17, 2018 P1/2, N=35, Active, not recruiting, Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Sep 2009 Trial primary completion date: Dec 2017 --> Dec 2018
- |||||||||| Phase classification, Enrollment change, Trial termination, Trial primary completion date: CINE-Cyst: Needle-based Confocal Laser Endomicroscopy on Pancreatic Cystic Lesions (clinicaltrials.gov) - Jan 17, 2018
P=N/A, N=10, Terminated, Trial primary completion date: Dec 2017 --> Dec 2018 Phase classification: P1 --> P=N/A | N=200 --> 10 | Recruiting --> Terminated | Trial primary completion date: Jun 2016 --> Jun 2017
- |||||||||| docetaxel / Generic mfg.
Trial completion, Metastases: Docetaxel and Lycopene in Metastatic Prostate Cancer (clinicaltrials.gov) - Jan 11, 2018 P1, N=24, Completed, Trial primary completion date: Jul 2019 --> Aug 2017 Active, not recruiting --> Completed
- |||||||||| Votrient (pazopanib) / Novartis, BeiGene
Trial primary completion date: Study To Assess Long Term Safety Of Pazopanib (clinicaltrials.gov) - Jan 8, 2018 P1, N=195, Active, not recruiting, Completed --> Terminated; Pfizer made a business-related decision on 04May2017 to terminate study based on change in portfolio prioritization, and is not due to safety or efficacy. Trial primary completion date: Dec 2017 --> Mar 2018
- |||||||||| Leukine (sargramostim) / Partner Therap, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Trial primary completion date, Combination therapy, Metastases: PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer (clinicaltrials.gov) - Jan 5, 2018 P1, N=51, Active, not recruiting, Trial primary completion date: Dec 2017 --> Mar 2018 Trial primary completion date: Jan 2018 --> Jan 2019
|